PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

Summary: PARP inhibitors have shown promising clinical activities for patients with BRCA mutations and are changing the landscape of ovarian cancer treatment. However, the therapeutic mechanisms of action for PARP inhibition in the interaction of tumors with the tumor microenvironment and the host i...

Full description

Bibliographic Details
Main Authors:	Liya Ding, Hye-Jung Kim, Qiwei Wang, Michael Kearns, Tao Jiang, Carolynn E. Ohlson, Ben B. Li, Shaozhen Xie, Joyce F. Liu, Elizabeth H. Stover, Brooke E. Howitt, Roderick T. Bronson, Suzan Lazo, Thomas M. Roberts, Gordon J. Freeman, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Jean J. Zhao
Format:	Article
Language:	English
Published:	Elsevier 2018-12-01
Series:	Cell Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211124718318175

Similar Items

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
by: Diana Zatreanu, et al.
Published: (2021-06-01)

Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas
by: Khyati Meghani, et al.
Published: (2018-04-01)

Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer
by: Young Eun Choi, et al.
Published: (2016-01-01)

PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers
by: Elizabeth K. Lee, et al.
Published: (2020-07-01)

Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors
by: Ciara C. O'Sullivan, et al.
Published: (2014-02-01)

PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
by: Tarra Evans, et al.
Published: (2017-04-01)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
by: Xia Ding, et al.
Published: (2016-08-01)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
by: Man Yee Keung, et al.
Published: (2020-03-01)

Current status and evolution of preclinical drug development models of epithelial ovarian cancer
by: Panagiotis A Konstantinopoulos, et al.
Published: (2013-12-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
by: Karolina N. Dziadkowiec, et al.
Published: (2017-02-01)

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
by: Elizabeth K. Lee, et al.
Published: (2020-07-01)

Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
by: Yosuke Hirotsu, et al.
Published: (2020-05-01)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
by: Eliana MC Tacconi, et al.
Published: (2019-07-01)

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
by: Timo Reisländer, et al.
Published: (2019-07-01)

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance
by: Yifan Wang, et al.
Published: (2019-12-01)

PARP Inhibition by Flavonoids Induced Selective Cell Killing to BRCA2-Deficient Cells
by: Cathy Su, et al.
Published: (2017-10-01)

Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy
by: Katarzyna Kluzek, et al.
Published: (2012-06-01)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018-03-01)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
by: Isabella Faraoni, et al.
Published: (2018-12-01)

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
by: Diar Aziz, et al.
Published: (2021-08-01)

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
by: Olga Kondrashova, et al.
Published: (2018-09-01)

Hypersensitivity of BRCA2 deficient cells to rosemary extract explained by weak PARP inhibitory activity
by: Cathy Su, et al.
Published: (2017-12-01)

PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer
by: Katarzyna Rygiel
Published: (2019-11-01)

Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers.
by: Kimiyo N Yamamoto, et al.
Published: (2014-01-01)

Investigation of response and resistance to PARP inhibition in mouse models of human BRCA2-mutant breast cancer
by: Ordonez, Liliana
Published: (2014)

Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations
by: Sachet A. Shukla, et al.
Published: (2017-02-01)

PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?
by: Joseph A. De Soto, Chu-Xia Deng
Published: (2006-01-01)

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
by: Katherine Sullivan-Reed, et al.
Published: (2018-06-01)

Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy
by: Caterina Fumagalli, et al.
Published: (2019-10-01)

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer
by: Hollis RL, et al.
Published: (2017-05-01)

Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients
by: See-Hyoung Park, et al.
Published: (2015-08-01)

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
by: Ewa Przybytkowski, et al.
Published: (2020-03-01)

Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses.
by: Tina M Sali, et al.
Published: (2015-12-01)

Parp1 protects against Aag-dependent alkylation-induced nephrotoxicity in a sex-dependent manner
by: Bronson, Roderick T., et al.
Published: (2017)

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
by: Marta Castroviejo‐Bermejo, et al.
Published: (2018-12-01)

Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
by: Di Zhang, et al.
Published: (2021-01-01)

860 Targeting immunosuppressive macrophages overcomes PARP-inhibitor resistance in BRCA1-associated triple-negative breast cancer
by: Elizabeth Mittendorf, et al.
Published: (2020-11-01)

DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors
by: Yaqin Shi, et al.
Published: (2019-06-01)

Exploring the Synergy between PARP and CHK1 Inhibition in Matched <i>BRCA2</i> Mutant and Corrected Cells
by: Hannah L Smith, et al.
Published: (2020-04-01)

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
by: Z Ping Lin, et al.
Published: (2018-01-01)